Results 161 to 170 of about 1,429,081 (399)
Enhancing the Promise of Drug Repositioning through Genetics
Frontiers in Pharmacology, 2017 The development of new drugs has become challenging as the necessary investments in time and money have increased while drug approval rates have decreased.
Jayne-Louise E. Pritchard +2 more
doaj +1 more source
Stem Cell Therapeutics: Exploring Newer Alternatives to Human Embryonic Stem Cells [PDF]
, 2008 Stem cells therapeutics has come a long way since stem cells and their potential was discovered for the first time. Intense research into cellular biology of stem cells has revealed that they possess immense potential for curing many human diseases ...
Garg, Abhishek D.
core
Molecular Oncology, EarlyView.The authors applied joint/mixed models that predict mortality of trifluridine/tipiracil‐treated metastatic colorectal cancer patients based on circulating tumor DNA (ctDNA) trajectories. Patients at high risk of death could be spared aggressive therapy with the prospect of a higher quality of life in their remaining lifetime, whereas patients with a ...
Matthias Unseld +7 more
wiley +1 more source
Generative Humanization for Therapeutic Antibodies [PDF]
arXivAntibody therapies have been employed to address some of today's most challenging diseases, but must meet many criteria during drug development before reaching a patient. Humanization is a sequence optimization strategy that addresses one critical risk called immunogenicity - a patient's immune response to the drug - by making an antibody more "human ...
arxiv
Hierarchical microplates as drug depots with controlled geometry, rigidity and therapeutic efficacy [PDF]
arXiv, 2019 A variety of microparticles have been proposed for the sustained and localized delivery of drugs whit the objective of increasing therapeutic indexes by circumventing filtering organs and biological barriers. Yet, the geometrical, mechanical and therapeutic properties of such microparticles cannot be simultaneously and independently tailored during the
arxiv
Molecular Oncology, EarlyView.Breast tumor samples scored for metabolic deregulation (M1 to M3) were given a hypoxia score (HS). The highest HS occurred in patients with strongest metabolic deregulation (M3), supporting tumor aggressiveness. HS correlated with the highest number of metabolic pathways in M1. This suggests hypoxia to be an early event in metabolic deregulation.
Raefa Abou Khouzam +2 more
wiley +1 more source
CONSIDERATIONS ON THE PATHOLOY AND THERAPEUTICS OF EPILEPSY [PDF]
, 1883 J. Leonard Corning
openalex +1 more source
Prospects for non-immunological molecular therapeutics in melanoma [PDF]
, 2010 In 2006 there were 60,000 new cases of cutaneous melanoma in the European Union and 13,000 deaths (www.europeancancerleagues.org). Currently available systemic treatment options for metastatic melanoma, including both cytotoxic and immunologic therapies,
Crown, John +4 more
core
Crosstalk between gut microbiota and tumor: tumors could cause gut dysbiosis and metabolic imbalance
Molecular Oncology, EarlyView.In this research, we analyzed the relationship between gut microbiota and tumor. We discovered that both subcutaneous and metastatic tumors would alter the composition and metabolic function of gut microbiota. Meanwhile, fecal microbiota transplantation also indicated the anti‐tumor role of the gut microbiota, revealing the crosstalk between tumor and ...
Siyuan Zhang +8 more
wiley +1 more source